Nanoparticle-Based Delivery Systems for Vaccines

被引:107
作者
Bezbaruah, Rajashri [1 ]
Chavda, Vivek P. [2 ]
Nongrang, Lawandashisha [1 ]
Alom, Shahnaz [1 ,3 ]
Deka, Kangkan [4 ]
Kalita, Tutumoni [5 ]
Ali, Farak [1 ,6 ]
Bhattacharjee, Bedanta [3 ]
Vora, Lalitkumar [7 ]
机构
[1] Dibrugarh Univ, Fac Sci & Engn, Dept Pharmaceut Sci, Dibrugarh 786004, Assam, India
[2] L M Coll Pharm, Dept Pharmaceut & Pharmaceut Technol, Ahmadabad 380008, Gujarat, India
[3] Girijananda Chowdhury Inst Pharmaceut Sci Tezpur, Dept Pharmacol, Tezpur 784501, Assam, India
[4] NETES Inst Pharmaceut Sci, Dept Pharmacognosy, Gauhati 781125, Assam, India
[5] Girijananda Chowdhury Inst Pharmaceut Sci, Dept Pharmaceut Chem, Gauhati 781017, Assam, India
[6] Girijananda Chowdhury Inst Pharmaceut Sci Tezpur, Dept Pharmaceut Chem, Tezpur 784501, Assam, India
[7] Queens Univ, Sch Pharm, Belfast BT97BL, North Ireland
关键词
nanoparticles; nanovaccine; nanocarriers; exosome; SOLID LIPID NANOPARTICLES; B SURFACE-ANTIGEN; NLRP3 INFLAMMASOME ACTIVATION; VIRUS-LIKE PARTICLES; T-CELL RESPONSES; DRUG-DELIVERY; GOLD NANOPARTICLES; HEPATITIS-B; IN-VIVO; SILICA NANOPARTICLES;
D O I
10.3390/vaccines10111946
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccination is still the most cost-effective way to combat infectious illnesses. Conventional vaccinations may have low immunogenicity and, in most situations, only provide partial protection. A new class of nanoparticle-based vaccinations has shown considerable promise in addressing the majority of the shortcomings of traditional and subunit vaccines. This is due to recent breakthroughs in chemical and biological engineering, which allow for the exact regulation of nanoparticle size, shape, functionality, and surface characteristics, resulting in improved antigen presentation and robust immunogenicity. A blend of physicochemical, immunological, and toxicological experiments can be used to accurately characterize nanovaccines. This narrative review will provide an overview of the current scenario of the nanovaccine.
引用
收藏
页数:42
相关论文
共 376 条
[91]   Male reproductive toxicity of inorganic nanoparticles in rodent models: A systematic review [J].
Dantas, Graziela P. F. ;
Ferraz, Fausto S. ;
Andrade, Lidia M. ;
Costa, Guilherme M. J. .
CHEMICO-BIOLOGICAL INTERACTIONS, 2022, 363
[92]   Nanovaccine: an emerging strategy [J].
Das, Amrita ;
Ali, Nahid .
EXPERT REVIEW OF VACCINES, 2021, 20 (10) :1273-1290
[93]   Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery [J].
Das, Surajit ;
Chaudhury, Anumita .
AAPS PHARMSCITECH, 2011, 12 (01) :62-76
[94]   Cellular uptake and cytotoxicity of PEGylated gold nanoparticles in C33A cervical cancer cells [J].
David, Shaquan ;
Patel, Devanshi Yogeshkumar ;
Cardona, Sandra M. ;
Kirby, Neil ;
Mayer, Kathryn M. .
NANO EXPRESS, 2022, 3 (02)
[95]   Nanoparticle therapeutics: an emerging treatment modality for cancer [J].
Davis, Mark E. ;
Chen, Zhuo ;
Shin, Dong M. .
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (09) :771-782
[96]   The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic [J].
Davis, Mark E. .
MOLECULAR PHARMACEUTICS, 2009, 6 (03) :659-668
[97]   Simultaneous Exposure of Different Nanoparticles Influences Cell Uptake [J].
de Boer, Isa ;
Richards, Ceri J. ;
Aberg, Christoffer .
PHARMACEUTICS, 2022, 14 (01)
[98]   Magnetic relaxometry as applied to sensitive cancer detection and localization [J].
De Haro, Leyma P. ;
Karaulanov, Todor ;
Vreeland, Erika C. ;
Anderson, Bill ;
Hathaway, Helen J. ;
Huber, Dale L. ;
Matlashov, Andrei N. ;
Nettles, Christopher P. ;
Price, Andrew D. ;
Monson, Todd C. ;
Flynn, Edward R. .
BIOMEDICAL ENGINEERING-BIOMEDIZINISCHE TECHNIK, 2015, 60 (05) :445-455
[99]   Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines [J].
De Serrano, Luis O. ;
Burkhart, David J. .
JOURNAL OF NANOBIOTECHNOLOGY, 2017, 15
[100]   Challenges in Development of Nanoparticle-Based Therapeutics [J].
Desai, Neil .
AAPS JOURNAL, 2012, 14 (02) :282-295